Li Ding

Associate Professor

Washington University in Saint Louis School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (35)

With the rapid growth of large-scale single-cell omic datasets, omic foundation models (FMs) have emerged as powerful tools for advancing research in life sciences and precision medicine. However, most existing omic FMs rely primarily on numerical transcriptomic data by sorting genes as sequences, while lacking explicit integration of biomedical prior knowledge and signaling interactions that are critical for scientific discovery. Here, we introduce the Text-Omic Signaling Graph (TOSG), a novel data structure that unifies human-interpretable biomedical textual knowledge, quantitative omic data, and signaling network information. Using this framework, we construct OmniCellTOSG, a large-scale resource comprising approximately half million meta-cell TOSGs derived from around 80 million single-cell and single-nucleus RNA-seq profiles across organs and diseases. We further develop CellTOSG-FM, a multimodal graph language FM, to jointly analyze textual, omic and signaling network context. Across diverse downstream tasks, CellTOSG-FM outperforms existing omic FMs, and provides interpretable insights into disease-associated targets and signaling pathways.

Year:

2026

Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.

Year:

2025

Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.

Year:

2025

NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank

Year:

2025

Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy. Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.

Year:

2025

Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.

Year:

2024

Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which are previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA-sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA-sequencing reiterated top candidates, further affirming the ability of single cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.

Year:

2024

Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.

Year:

2024

Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.

Year:

2024

Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (54)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Matthew H Bailey

Assistant Professor

Brigham Young University

UNITED STATES
View details

Jose G. Trevino

Virginia Commonwealth University

UNITED STATES
View details

Feng Chen

Professor

Washington University in St. Louis

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Cornelius von Morze

-

UNITED STATES
View details

Gerburg Wulf

Harvard University

UNITED STATES
View details

Sherri Davies

Senior Scientist

Washington University in St. Louis

UNITED STATES
View details

Min Jin Ha

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Song Cao

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

William Buchser

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Peter Robinson

Professor for Medical Computer Science

The Jackson Laboratory for Genomic Medicine

UNITED STATES
View details

Jeffrey Chuang

Jackson Laboratory

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

David G. DeNardo

Professor of Medicine

Washington University School of Medicine

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Mark Fiala

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Shidan Wang

-

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

Kooresh Shoghi

Professor

Washington University in St. Louis

UNITED STATES
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Bryan Welm

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

Jason M. Held

Washington University School of Medicine

UNITED STATES
View details

Xuelin Huang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John F. DiPersio

Director, Center for Gene and Cellular Immunotherapy

Washington University in St. Louis

UNITED STATES
View details

Shunqiang Li

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Ying Zhu

Genentech Inc

UNITED STATES
View details

Scott Goldsmith

Assistant Professor

City Of Hope National Medical Center

UNITED STATES
View details

Kian-Huat Lim

Associate Professor

Washington University

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Luis G Carvajal‐Carmona

Professor

University of California, Davis

UNITED STATES
View details

Michael Province

Professor, Head Division of Statistical Genomics

Washington University in St. Louis

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Mashl

Washington University in St. Louis

UNITED STATES
View details

Chong-xian Pan

Professor

university of california davis medical center

UNITED STATES
View details

Tao Liu

Sr. Staff Scientist

Pacific Northwest National Laboratory

UNITED STATES
View details

Carol Bult

Professor and Knowlton Family Chair

Jackson Laboratory

UNITED STATES
View details

Ravi Vij

Washington University School of Medicine

UNITED STATES
View details

Chia-Feng Tsai

Scorpion Therapeutics (United States)

UNITED STATES
View details

Salma Kaochar

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Leah Gehrs

The University of Alabama

UNITED STATES
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

J. Chuck Harrell

Virginia Commonwealth University

UNITED STATES
View details

Michael Lewis

Baylor College of Medicine

UNITED STATES
View details

jingqin luo

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Soner Koc

GlaxoSmithKline Research and Development

UNITED STATES
View details

Michael Rettig

Washington University in St. Louis

UNITED STATES
View details

Guanghua Xiao

-

UNITED STATES
View details

Yang Xie

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details